Lookup NU author(s): Dr Helen Tuppen,
Professor Robert Taylor
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
Mutations in mitochondrial (mt) genes coding for mt-tRNAs are responsible for a range of syndromes, for which no effective treatment is available. We recently showed that the carboxy-terminal domain (Cterm) of human mt-leucyl tRNA synthetase rescues the pathologic phenotype associated either with the m.3243A>G mutation in mt-tRNA(Leu(UUR)) or with mutations in the mt-tRNA(Ile), both of which are aminoacylated by Class I mt-aminoacyl-tRNA synthetases (mt-aaRSs). Herewe show, by using the human transmitochondrial cybrid model, that the Cterm is also able to improve the phenotype caused by the m. 8344A>G mutation in mt-tRNA(Lys), aminoacylated by a Class II aaRS. Importantly, we demonstrate that the same rescuing ability is retained by two Cterm-derived short peptides, beta 30_31 and beta 32_33, which are effective towards both the m. 8344A>G and the m. 3243A>G mutations. Furthermore, we provide in vitro evidence that these peptides bind with high affinity wild-type and mutant human mt-tRNA(Leu(UUR)) and mt-tRNA(Lys), and stabilize mutant mt-tRNA(Leu(UUR)). In conclusion, we demonstrate that small Cterm-derived peptides can be effective tools to rescue cellular defects caused by mutations in a wide range of mt-tRNAs.
Author(s): Perli E, Fiorillo A, Giordano C, Pisano A, Montanari A, Grazioli P, Campese AF, Di Micco P, Tuppen HA, Genovese I, Poser E, Preziuso C, Taylor RW, Morea V, Colotti G, d'Amati G
Publication type: Article
Publication status: Published
Journal: Human Molecular Genetics
Print publication date: 01/03/2016
Online publication date: 31/12/2015
Acceptance date: 18/12/2015
ISSN (print): 0964-6906
ISSN (electronic): 1460-2083
Publisher: Oxford University Press
Altmetrics provided by Altmetric